F Beisse1, R Diem2. 1. Universitäts-Augenklinik Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland. flemming.beisse@med.uni-heidelberg.de. 2. Neurologische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
Abstract
BACKGROUND: To date, high-dose corticosteroids constitute the only established treatment of acute optic neuritis (ON); however, steroids cannot prevent the loss of retinal nerve fibers. New acute therapeutic drugs are therefore being sought for a reduction of ganglion cell death. METHODS: Literature search comprising clinical studies on treatment of ON with immunomodulatory and neuroprotective drugs. RESULTS: For the immunomodulatory drug simvastatin some evidence for long-term benefits was shown, particularly regarding visual evoked potentials. For the neuroprotective substance memantine a potential positive effect on retinal nerve fiber layer (RNFL) thickness was revealed. Likewise in one publication a reduction in loss of RNFL thickness could be demonstrated for erythropoietin and this drug is currently being extensively investigated in a phase III randomized controlled trial (RCT). The results of studies with phenytoin, amiloride and anti-leucine-rich repeat and immunoglobulin domain containing 1 protein (anti-LINGO-1) antibodies are awaiting publication. CONCLUSION: According to the data from recent treatment trials, there is hope that neuronal loss in ON can be reduced with the help of immunomodulatory substances, such as simvastatin or neuroprotective agents, such as memantine and erythropoietin.
BACKGROUND: To date, high-dose corticosteroids constitute the only established treatment of acute optic neuritis (ON); however, steroids cannot prevent the loss of retinal nerve fibers. New acute therapeutic drugs are therefore being sought for a reduction of ganglion cell death. METHODS: Literature search comprising clinical studies on treatment of ON with immunomodulatory and neuroprotective drugs. RESULTS: For the immunomodulatory drug simvastatin some evidence for long-term benefits was shown, particularly regarding visual evoked potentials. For the neuroprotective substance memantine a potential positive effect on retinal nerve fiber layer (RNFL) thickness was revealed. Likewise in one publication a reduction in loss of RNFL thickness could be demonstrated for erythropoietin and this drug is currently being extensively investigated in a phase III randomized controlled trial (RCT). The results of studies with phenytoin, amiloride and anti-leucine-rich repeat and immunoglobulin domain containing 1 protein (anti-LINGO-1) antibodies are awaiting publication. CONCLUSION: According to the data from recent treatment trials, there is hope that neuronal loss in ON can be reduced with the help of immunomodulatory substances, such as simvastatin or neuroprotective agents, such as memantine and erythropoietin.
Authors: Anna Tsakiri; Klaus Kallenbach; Dan Fuglø; Benedikte Wanscher; Henrik Larsson; Jette Frederiksen Journal: Mult Scler Date: 2011-09-15 Impact factor: 6.312
Authors: Andrew P D Henderson; Daniel R Altmann; Anand S Trip; Constantinos Kallis; Steve J Jones; Patricio G Schlottmann; David F Garway-Heath; Gordon T Plant; David H Miller Journal: Brain Date: 2010-06-20 Impact factor: 13.501
Authors: Kurt-Wolfram Sühs; Katharina Hein; Muriel B Sättler; Anke Görlitz; Christoph Ciupka; Kerstin Scholz; Barbara Käsmann-Kellner; Panagiotis Papanagiotou; Nina Schäffler; Cordula Restemeyer; Diana Bittersohl; Andrea Hassenstein; Berthold Seitz; Wolfgang Reith; Klaus Fassbender; Reinhard Hilgers; Christoph Heesen; Mathias Bähr; Ricarda Diem Journal: Ann Neurol Date: 2012-08 Impact factor: 10.422
Authors: Justin B McKee; John Elston; Nikos Evangelou; Stephen Gerry; Lars Fugger; Christopher Kennard; Yazhuo Kong; Jacqueline Palace; Matthew Craner Journal: BMJ Open Date: 2015-11-09 Impact factor: 2.692